"Immunogenicity, Vaccine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The capacity of VACCINES to stimulate the ADAPTIVE IMMUNE RESPONSE to produce antibodies and antigen-specific T-CELL responses.
| Descriptor ID |
D000071497
|
| MeSH Number(s) |
G12.070.500 G12.450.050.370.500 G12.450.050.460 G12.513
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunogenicity, Vaccine".
Below are MeSH descriptors whose meaning is more specific than "Immunogenicity, Vaccine".
This graph shows the total number of publications written about "Immunogenicity, Vaccine" by people in this website by year, and whether "Immunogenicity, Vaccine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 3 | 1 | 4 |
| 2017 | 0 | 3 | 3 |
| 2018 | 2 | 2 | 4 |
| 2019 | 4 | 6 | 10 |
| 2020 | 1 | 4 | 5 |
| 2021 | 2 | 7 | 9 |
| 2022 | 2 | 4 | 6 |
| 2023 | 1 | 6 | 7 |
| 2024 | 2 | 5 | 7 |
| 2025 | 9 | 1 | 10 |
| 2026 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunogenicity, Vaccine" by people in Profiles.
-
A Phase 1 Double-Blinded Trial to Evaluate Safety, Immunogenicity, and Dosing of Measles-Vectored Chikungunya Virus Vaccine (MV-CHIK) in Healthy Adults. J Infect Dis. 2026 Mar 17; 233(3):e641-e645.
-
Impact of prior SARS-CoV-2 acquisition on binding and neutralizing antibody responses following COVID-19 vaccination: A cross-protocol analysis of individual-level data from six phase 3 clinical trials. Vaccine. 2026 Apr 02; 77:128380.
-
Efficacy, safety, and immunogenicity of Lassa fever vaccines: A living systematic review and landscape analysis of vaccine candidates. PLoS One. 2025; 20(12):e0338128.
-
Evaluation of the safety and immunogenicity of two fractional intradermal regimens of MVA-BN compared to standard dose vaccination. Vaccine. 2026 Jan 01; 69:127959.
-
Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenstr?m macroglobulinemia. Blood Adv. 2025 Sep 23; 9(18):4568-4579.
-
Recombinant quadrivalent influenza vaccine (RIV) induces robust cell-mediated and HA-specific B cell humoral immune responses among healthcare personnel. Vaccine. 2025 Aug 13; 61:127361.
-
Safety, immunogenicity, and effectiveness of chikungunya vaccines in pregnant persons, children, and adolescents: a protocol for a living systematic review and meta-analysis. Reprod Health. 2025 Apr 18; 22(1):56.
-
Safety, immunogenicity, efficacy, and effectiveness of Lassa fever vaccines in pregnant persons, children, and adolescents: a protocol for a living systematic review and meta-analysis. Reprod Health. 2025 Apr 15; 22(1):53.
-
rVSV?G-ZEBOV-GP Vaccine Is Highly Immunogenic and Efficacious Across a Wide Dose Range in a Nonhuman Primate EBOV Challenge Model. Viruses. 2025 02 28; 17(3).
-
Immunogenicity and Reactogenicity of High- or Standard-Dose Influenza Vaccine in a Second Consecutive Influenza Season. J Infect Dis. 2025 Feb 04; 231(1):e123-e131.